melatonin has been researched along with Amyloid Deposits in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease is a neurodegenerative disorder associated with age, and is characterized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles." | 2.72 | Regulation of Melatonin and Neurotransmission in Alzheimer's Disease. ( Fung, ML; Lim, LW; Ng, J; Roy, J; Tsui, KC, 2021) |
| "The typical symptoms of patients with Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and tau hyperphosphorylation." | 1.72 | Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease. ( Tsai, YL; Wang, YF; Yen, CT, 2022) |
| "Similarly, amyloid plaque loads in hippocampus and frontal cortex, as well as plasma Aβ1-42 levels, were significantly reduced by MEL in a receptor-independent manner, in contrast to MEL's efficacy in reducing cortical antioxidant gene expression (Catalase, SOD1, Glutathione Peroxidase-1, Nrf2) only when receptors were present." | 1.42 | Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice. ( Bradshaw, PC; Delic, V; O'Neal-Moffitt, G; Olcese, J, 2015) |
| "Melatonin has been proposed as a treatment for Alzheimer's disease based on the demonstration of antioxidant and "anti-amyloid" effects in vitro and in vivo." | 1.33 | Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. ( Jones, R; Kulhanek, D; Nowlin, J; Praticò, D; Quinn, J; Rokach, J; Stackman, R, 2005) |
| "Melatonin is a product that plays not only a major role in the regulation of the circadian rhythms but may also exert neuroprotective effects in AD." | 1.32 | Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. ( Hofman, MA; Kamphorst, W; Liu, RY; Swaab, DF; Zhou, JN, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Necula, M | 1 |
| Kayed, R | 1 |
| Milton, S | 1 |
| Glabe, CG | 1 |
| Tsai, YL | 1 |
| Yen, CT | 1 |
| Wang, YF | 1 |
| Roy, J | 1 |
| Tsui, KC | 1 |
| Ng, J | 1 |
| Fung, ML | 1 |
| Lim, LW | 1 |
| Dai, Y | 1 |
| Peng, L | 1 |
| Liu, Y | 1 |
| Xu, Y | 1 |
| Qiao, J | 1 |
| Aarabi, MH | 1 |
| Mirhashemi, SM | 1 |
| Vincent, B | 1 |
| Sulkava, S | 1 |
| Muggalla, P | 1 |
| Sulkava, R | 1 |
| Ollila, HM | 1 |
| Peuralinna, T | 1 |
| Myllykangas, L | 1 |
| Kaivola, K | 1 |
| Stone, DJ | 1 |
| Traynor, BJ | 1 |
| Renton, AE | 1 |
| Rivera, AM | 1 |
| Helisalmi, S | 1 |
| Soininen, H | 1 |
| Polvikoski, T | 1 |
| Hiltunen, M | 1 |
| Tienari, PJ | 1 |
| Huttunen, HJ | 1 |
| Paunio, T | 1 |
| Gerenu, G | 1 |
| Liu, K | 1 |
| Chojnacki, JE | 1 |
| Saathoff, JM | 1 |
| Martínez-Martín, P | 1 |
| Perry, G | 1 |
| Zhu, X | 1 |
| Lee, HG | 1 |
| Zhang, S | 1 |
| O'Neal-Moffitt, G | 1 |
| Delic, V | 1 |
| Bradshaw, PC | 1 |
| Olcese, J | 1 |
| Zhou, JN | 1 |
| Liu, RY | 1 |
| Kamphorst, W | 1 |
| Hofman, MA | 1 |
| Swaab, DF | 1 |
| Quinn, J | 1 |
| Kulhanek, D | 1 |
| Nowlin, J | 1 |
| Jones, R | 1 |
| Praticò, D | 1 |
| Rokach, J | 1 |
| Stackman, R | 1 |
2 reviews available for melatonin and Amyloid Deposits
| Article | Year |
|---|---|
Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biogenic Monoamines; Disease Susceptibility; Humans; Melat | 2021 |
Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Humans; Me | 2018 |
9 other studies available for melatonin and Amyloid Deposits
| Article | Year |
|---|---|
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Humans; Plaque, Amyloid; Protein Structu | 2007 |
Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Calcium; Humans; Ions; Melatonin; Osteoporosis | 2022 |
Melatonin binds with high affinity and specificity to beta-amyloid: LC-MS provides insight into Alzheimer's disease treatment.
Topics: Alzheimer Disease; Chromatography, Liquid; Humans; Melatonin; Plaque, Amyloid; Tandem Mass Spectrome | 2021 |
To estimate effective antiamyloidogenic property of melatonin and fisetin and their actions to destabilize amyloid fibrils.
Topics: Amyloid; Amyloid beta-Peptides; Flavonoids; Flavonols; Melatonin; Plaque, Amyloid; Protein Conformat | 2017 |
Melatonin receptor type 1A gene linked to Alzheimer's disease in old age.
Topics: Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Brain; | 2018 |
Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide ameliorates AD-like pathology in the APP/PS1 mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Brain; Coumarins; Dis | 2015 |
Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anxiety; Disease | 2015 |
Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Female; Humans; Male; Melatonin; Plaque | 2003 |
Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials.
Topics: Aging; Amyloid beta-Peptides; Animals; Antioxidants; Astrocytes; Lipid Peroxidation; Melatonin; Mice | 2005 |